Table 3.
Numbers and proportions of cases of interval cancer and second round screen-detected cancer, and likelihood of presentation, by study group and interval cancer status
| Reinvited | Reattending | ||||||||
| Women (n) | Women (n) | ||||||||
| Study group | Total (100%) | Yes | No | % Yes (95% CI) | Odds ratioa (95% CI) | Yes | No | % Yes (95% CI) | Odds ratioa (95% CI) |
| All groups | |||||||||
| All | 113,409 | 102,772 | 10,637 | 90.6 (90.5–90.8) | 97,062 | 16,347 | 85.6 (85.4–85.8) | ||
| With interval cancer | 375 | 102 | 273 | 27.2 (22.7–31.7) | 72 | 303 | 19.2 (15.2–23.2) | ||
| Without interval cancer | 113,034 | 102,670 | 10,364 | 90.8 (90.7–91.0) | 96,990 | 16,044 | 85.8 (85.6–86.0) | ||
| Nonassessed normal | |||||||||
| All | 108,617 | 98,561 | 10,056 | 90.7 (90.6–90.9) | 1.00 | 93,081 | 15,536 | 85.7 (85.5–85.9) | 1.00 |
| With interval cancer | 329 | 97 | 232 | 29.5 (24.6–34.4) | 69 | 260 | 21.0 (16.6–25.4) | ||
| Without interval cancer | 108,288 | 98,464 | 9824 | 90.9 (90.8–91.1) | 93,012 | 9824 | 85.9 (85.7–86.1) | ||
| Assessed normal | |||||||||
| All | 4278 | 3782 | 496 | 88.4 (87.4–89.4) | 0.78 (0.71–0.86) | 3572 | 706 | 83.5 (82.4–84.6) | 0.84 (0.78–0.92) |
| With interval cancer | 42 | 5 | 37 | 11.9 (2.1–21.7) | 3 | 39 | 7.1 (0–14.9) | ||
| Without interval cancer | 4236 | 3777 | 459 | 89.2 (88.2–90.1) | 3569 | 667 | 84.3 (83.2–85.4) | ||
| Assessed benign | |||||||||
| All | 514 | 429 | 85 | 83.5 (80.3–86.7) | 0.51 (0.41–0.65) | 409 | 105 | 79.6 (76.1–83.1) | 0.65 (0.52–0.81) |
| With interval cancer | 4 | 0 | 4 | 0 | 0 | 4 | 0 | ||
| Without interval cancer | 510 | 429 | 81 | 84.1 (81.0–87.3) | 409 | 101 | 80.2 (76.7–83.7) | ||
| All assessed | |||||||||
| All | 4792 | 4211 | 581 | 87.9 (87.0–88.8) | 0.74 (0.68–0.81) | 3981 | 811 | 83.1 (82.0–84.1) | 0.82 (0.76–0.89) |
| With interval cancer | 46 | 5 | 41 | 10.9 (1.9–19.9) | 3 | 43 | 6.5 (0–13.7) | ||
| Without interval cancer | 4746 | 4206 | 540 | 88.6 (87.7–89.5) | 3978 | 768 | 83.8 (82.8–84.9) | ||
a Odds ratios of the likelihood of reinvitation or reattendance among assessed normal, assessed benign or all assessed women versus that in the nonassessed normal group.